Hip Fracture Risk Up With Drug Holiday From Risedronate vs Alendronate
After 3 or more years of therapy, drug holidays from risedronate versus alendronate linked to 18% increase in hip fracture risk
Bone Disorders
Prevalence of Fragility Fractures Up With E-Cigarette Use
Among U.S. adults, prevalence of fragility fractures increased for former and current e-cigarette users compared with never users
Voxzogo Gets FDA Approval for Achondroplasia
The approval was based on data from a phase 3 study that evaluated the efficacy and safety of Voxzogo in 121 children with genetically-confirmed achondroplasia.
Fracture Risk Assessed Among Users of SGLT-2 Inhibitors vs Other Antidiabetic Agents
The study authors conducted a nationwide cohort study that included 137,667 Medicare beneficiaries.
Long-Term Bone Loss Studied in Postmenopausal Women
Lower baseline BMI and greater increase in BMI appear to be protective against postmenopausal bone loss
Abaloparatide Looks Promising for Men With Osteoporosis
The phase 3 ATOM study evaluated the efficacy and safety of abaloparatide in 228 men with osteoporosis.
Tymlos Label Update Highlights Bone Building Mechanism of Action
The update is based on data from an open-label, single-arm histomorphometry study.
Osteoporosis Treatments Compared to Assess Effects on Bone Mineral Density
The network meta-analysis compared the effects of 9 osteoporosis drugs on BMD.
Study: Etelcalcetide Can Be Used Safely in Diabetic Nephropathy
Etelcalcetide use in patients with diabetic nephropathy might protect against development of adynamic bone disease, according to investigators.
Erythropoietin May Up Risk for Hip Fracture in Hemodialysis Patients
Risk for hip fracture increased with EPO doses of 50 to 149, 150 to 299, and 300 or greater vs <50 units/kg/week
